Head-to-head evidence
Interferon-beta1 vs Rebif (interferon beta 1a)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: Type I interferon receptor · full Multiple Sclerosis pipeline
Interferon-beta1
Marketed by Biogen
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Rebif (interferon beta 1a)
Marketed by Merck KGaA and partners
NCT00110396 · Phase 3 · completed
The study was a single-group, open-label trial without randomization or a placebo or active comparator. Its primary endpoint was a laboratory antibody measure rather than a clinical outcome; 45 of 259 assessed participants were neutralising-antibody positive at week 96, but the design did not provide a controlled comparison.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Interferon-beta1's landscape · Rebif (interferon beta 1a)'s landscape